Your answers are very speculative when they could easily be verified.

How big are the operating loans of a pharmaceutical company? Specifically those who mature over the course of a development cycle?

Construction is commonly financed through loans which get covered in the sales price, so it’s a tried and true method with foreseeable margins and robust risk assessment. And notably covered in the annual reports of their finances.

I find it hard to believe pharmaceuticals should be very different, and the lack of receipts makes it very dubious that’s the costs they’re covering.

You made the claim though, please provide some evidence to back it up.